Preventing arthritis relapse
The project consortium focuses on:
Investigating the possible superiority of early treatment of psoriatic spondyloarthritis (pSpA) patients with biologic treatment as compared to the standard of care.
Delineating the window of opportunity for pSpA: a transient time frame in which a disease is more susceptible to treatment.
Unravelling new biomarkers of therapy response using cutting-edge single-cell technology and epigenetic profiling.
Determining health-economic and societal impact of earlier and more biologic intensive treatment of patients with recent onset pSpA.
Increasing awareness among referring physicians and patient-advocacy groups about the value of early recognition and treatment in rheumatology.
In short, SPARTACUS will explore the societal and economic impact of this new, temporally restricted biologics treatment and improved diagnosis.